Chronic Lymphocytic Leukemia Clinical Trial

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

Summary

Open-label pilot study to determine safety and efficacy of CART-19 cells in combination with ibrutinib. The target dose will be 1-5x10xE8 CART-19 transduced cells administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3. 15 evaluable subjects (adults) with relapsed or refractory leukemia-cll/" >CLL/SLL who have achieved partial response or stable disease on ibrutinib therapy will be eligible to receive CART-19 therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Documented CD19+ CLL or SLL
Successful test expansion -cells (as described in Section 6.1)

Patients must have failed at least 1 prior regimen before Ibrutinib (not including single agent rituximab or single agent corticosteroids)

a. Note: Any relapse after prior autologous SCT will make the patient eligible regardless of other prior therapy.

Patients must be currently receiving ibrutinib for at least 6 months prior to enrollment in the study and:

Not experiencing any ≥ grade 2 non-hematologic ibrutinib-related toxicity
The best response to ibrutinib therapy must not have exceeded partial response or stable disease (i.e. no CR or CRi)
Note: Patients carrying a deletion at chromosome 17p (i.e. del[17p]), and/or TP53, BTK, and at the PLCγ2 loci mutations, will be eligible if they are receiving frontline therapy with ibrutinib.
ECOG Performance status 0 or 1
18 years of age and older

Adequate organ system function including:

Creatinine < 1.6 mg/dl
ALT/AST < 3x upper limit of normal
Total Bilirubin <2.0 mg/dl with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is ≥ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN.

Patients with relapsed disease after prior allogeneic SCT (myeloablative or nonmyeloablative) will be eligible if they meet all other inclusion criteria and:

Have no active GVHD and require no immunosuppression
Are more than 6 months from transplant
No contraindications for leukapheresis
Left Ventricular Ejection fraction >40%
Gives voluntary informed consent
Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria:

CLL patients with known or suspected transformed disease (i.e. Richter's transformation). Note: biopsy proven absence of transformation is not required.
Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion.
Uncontrolled active infection.
Active hepatitis B or hepatitis C infection.
Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary.
Any uncontrolled active medical disorder that would preclude participation as outlined.
HIV infection.
Patients with active CNS involvement with malignancy. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment.
Class III/IV cardiovascular disability according to the New York Heart Association Classification.
Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollment.
Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Early Phase 1

Estimated Enrollment:

20

Study ID:

NCT02640209

Recruitment Status:

Terminated

Sponsor:

University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Abramson Cancer Center of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Early Phase 1

Estimated Enrollment:

20

Study ID:

NCT02640209

Recruitment Status:

Terminated

Sponsor:


University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.